S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   322.67 (-0.28%)
AAPL   127.06 (-0.57%)
MSFT   235.40 (-0.65%)
FB   265.35 (+0.17%)
GOOGL   2,081.27 (+0.56%)
TSLA   709.93 (-1.18%)
AMZN   3,147.00 (+0.03%)
NVDA   548.21 (-0.99%)
BABA   240.79 (-0.37%)
CGC   36.03 (+3.74%)
GE   13.09 (-0.15%)
MU   94.10 (-0.70%)
NIO   45.03 (-9.51%)
AMD   85.95 (-0.51%)
T   28.27 (+0.64%)
F   12.09 (+0.92%)
ACB   11.73 (+6.25%)
DIS   196.45 (+0.75%)
BA   223.23 (-0.52%)
NFLX   551.57 (+0.17%)
BAC   35.88 (+0.25%)
S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   322.67 (-0.28%)
AAPL   127.06 (-0.57%)
MSFT   235.40 (-0.65%)
FB   265.35 (+0.17%)
GOOGL   2,081.27 (+0.56%)
TSLA   709.93 (-1.18%)
AMZN   3,147.00 (+0.03%)
NVDA   548.21 (-0.99%)
BABA   240.79 (-0.37%)
CGC   36.03 (+3.74%)
GE   13.09 (-0.15%)
MU   94.10 (-0.70%)
NIO   45.03 (-9.51%)
AMD   85.95 (-0.51%)
T   28.27 (+0.64%)
F   12.09 (+0.92%)
ACB   11.73 (+6.25%)
DIS   196.45 (+0.75%)
BA   223.23 (-0.52%)
NFLX   551.57 (+0.17%)
BAC   35.88 (+0.25%)
S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   322.67 (-0.28%)
AAPL   127.06 (-0.57%)
MSFT   235.40 (-0.65%)
FB   265.35 (+0.17%)
GOOGL   2,081.27 (+0.56%)
TSLA   709.93 (-1.18%)
AMZN   3,147.00 (+0.03%)
NVDA   548.21 (-0.99%)
BABA   240.79 (-0.37%)
CGC   36.03 (+3.74%)
GE   13.09 (-0.15%)
MU   94.10 (-0.70%)
NIO   45.03 (-9.51%)
AMD   85.95 (-0.51%)
T   28.27 (+0.64%)
F   12.09 (+0.92%)
ACB   11.73 (+6.25%)
DIS   196.45 (+0.75%)
BA   223.23 (-0.52%)
NFLX   551.57 (+0.17%)
BAC   35.88 (+0.25%)
S&P 500   3,897.71 (-0.11%)
DOW   31,570.49 (+0.11%)
QQQ   322.67 (-0.28%)
AAPL   127.06 (-0.57%)
MSFT   235.40 (-0.65%)
FB   265.35 (+0.17%)
GOOGL   2,081.27 (+0.56%)
TSLA   709.93 (-1.18%)
AMZN   3,147.00 (+0.03%)
NVDA   548.21 (-0.99%)
BABA   240.79 (-0.37%)
CGC   36.03 (+3.74%)
GE   13.09 (-0.15%)
MU   94.10 (-0.70%)
NIO   45.03 (-9.51%)
AMD   85.95 (-0.51%)
T   28.27 (+0.64%)
F   12.09 (+0.92%)
ACB   11.73 (+6.25%)
DIS   196.45 (+0.75%)
BA   223.23 (-0.52%)
NFLX   551.57 (+0.17%)
BAC   35.88 (+0.25%)
Log in
NYSEARCA:BBP

Virtus LifeSci Biotech Products ETF Stock Forecast, Price & News

$55.52
+0.63 (+1.15 %)
(As of 03/1/2021 12:00 AM ET)
Add
Today's Range
$55.40
Now: $55.52
$55.68
50-Day Range
$54.89
MA: $57.52
$61.28
52-Week Range
$30.83
Now: $55.52
$61.39
Volume826 shs
Average Volume1,329 shs
Market Capitalization$30.54 million
P/E RatioN/A
Dividend Yield0.00%
BetaN/A

Basic Details

Issuer Virtus
Fund NameVirtus LifeSci Biotech Products ETF
Tax ClassificationRegulated Investment Company
SymbolNYSEARCA:BBP
Inception Date12/16/2014
Fund ManagerMatthew B. Brown, Seth Kadushin
WebN/A
PhoneN/A

Fund Focus

Asset ClassEquity
BenchmarkLifeSci Biotechnology Products Index
CategorySector
FocusHealth Care
Development LevelDeveloped Markets
RegionNorth America

Fund Statistics

Assets Under Management$27.63 million
Average Daily Volume$2,147.30
Discount/Premium-0.07%

ETF Expenses

Management Fee0.79%
Other Expenses0.00%
Total Expenses0.79%
Fee Waiver0.00%
Net Expenses0.79%

Administrator, Advisor and Custodian

AdministratorVirtus ETF Solutions, LLC
AdvisorVirtus ETF Advisers LLC
CustodianThe Bank of New York Mellon Corporation
DistributorETF Distributors LLC
Transfer AgentThe Bank of New York Mellon Corporation
Trustee
Lead Market MakerVirtu Financial

Geographic Exposure of BBP

Currency Exposure of BBP

Sector Exposure of BBP

Industry Exposure of BBP

$55.52
+0.63 (+1.15 %)
(As of 03/1/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BBP News and Ratings via Email

Sign-up to receive the latest news and ratings for BBP and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Virtus LifeSci Biotech Products ETF (NYSEARCA:BBP) Frequently Asked Questions

What stocks does MarketBeat like better than Virtus LifeSci Biotech Products ETF?

Wall Street analysts have given Virtus LifeSci Biotech Products ETF a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Virtus LifeSci Biotech Products ETF wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How has Virtus LifeSci Biotech Products ETF's stock been impacted by Coronavirus (COVID-19)?

Virtus LifeSci Biotech Products ETF's stock was trading at $38.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, BBP stock has increased by 44.7% and is now trading at $55.5222.
View which stocks have been most impacted by COVID-19
.

What other stocks do shareholders of Virtus LifeSci Biotech Products ETF own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Virtus LifeSci Biotech Products ETF investors own include (SNY), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Intel (INTC), Micron Technology (MU), Virtus LifeSci Biotech Clinical Trials ETF (BBC), Quest Diagnostics (DGX), Pfizer (PFE), Simon Property Group (SPG) and Cidara Therapeutics (CDTX).

What is Virtus LifeSci Biotech Products ETF's stock symbol?

Virtus LifeSci Biotech Products ETF trades on the New York Stock Exchange (NYSE)ARCA under the ticker symbol "BBP."

How do I buy shares of Virtus LifeSci Biotech Products ETF?

Shares of BBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Virtus LifeSci Biotech Products ETF's stock price today?

One share of BBP stock can currently be purchased for approximately $55.52.

How much money does Virtus LifeSci Biotech Products ETF make?

Virtus LifeSci Biotech Products ETF has a market capitalization of $30.54 million.


This page was last updated on 3/2/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.